ReWalk Robotics (NASDAQ:LFWD) Rating Reiterated by HC Wainwright

ReWalk Robotics (NASDAQ:LFWD)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $9.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 80.36% from the company’s previous close.

ReWalk Robotics Price Performance

NASDAQ LFWD opened at $4.99 on Monday. ReWalk Robotics has a one year low of $3.90 and a one year high of $9.10. The firm has a 50 day simple moving average of $5.60. The stock has a market capitalization of $42.42 million, a price-to-earnings ratio of -1.74 and a beta of 2.00.

ReWalk Robotics (NASDAQ:LFWD) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.56. ReWalk Robotics had a negative net margin of 159.76% and a negative return on equity of 28.19%. The firm had revenue of $6.88 million for the quarter, compared to analyst estimates of $7.20 million. As a group, sell-side analysts anticipate that ReWalk Robotics will post -1.82 earnings per share for the current fiscal year.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic.